Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Z Gerontol Geriatr ; 56(5): 402-407, 2023 Aug.
Article in German | MEDLINE | ID: mdl-35522313

ABSTRACT

BACKGROUND: In Germany geriatric outpatient care is predominantly done by family doctors and general practitioners (GP). There are regionally different concepts for additional specialized geriatric outpatient care but they have not yet been validated and established. Still, it remains unclear whether a geriatric patient has to be diagnosed rather in a specialized outpatient or inpatient setting. The aim of the present study is the profiling of geriatric outpatients to find key distinctions from geriatric patients that have to be admitted to hospital. METHODS: Retrospective data analysis of patients sent to a specialized geriatric outpatient clinic by their GP, compared with data of geriatric inpatients sent to hospital by their GP during the same time period. Study parameters comprised elements of the comprehensive geriatric assessment as well as results of routinely applied laboratory tests. RESULTS: Patients sent to the specialized geriatric outpatient clinic showed better results of functional assessments. Regression analysis: improvement of Barthel Index, GFR and total protein increased the chance of outpatient treatment. CONCLUSION: Early identification of geriatric patients who can be treated in a specialized outpatient setting would ease the burden for GPs by interdisciplinary cooperation and prevent cost-intensive readmissions to hospital.


Subject(s)
Ambulatory Care Facilities , Ambulatory Care , Humans , Aged , Retrospective Studies , Outpatients , Inpatients
2.
Methods Mol Biol ; 1349: 177-200, 2016.
Article in English | MEDLINE | ID: mdl-26458837

ABSTRACT

Orf virus (ORFV) is an epitheliotropic poxvirus, which belongs to the genus Parapoxvirus. Among them the highly attenuated, apathogenic strain D1701-V is regarded as a promising candidate for novel virus vector vaccines. Our recent work demonstrated that those ORFV-based recombinants were able to induce protective, long-lasting immunity in various hosts that are non-permissive for ORFV. In this chapter we describe procedures for the generation, selection, propagation, and titration of ORFV recombinants as well as transgene detection by PCR or immunohistochemical staining.


Subject(s)
Antibodies, Viral/immunology , Orf virus/genetics , Viral Vaccines/genetics , Antibodies, Viral/genetics , Genetic Vectors , Humans , Orf virus/immunology , Parapoxvirus/genetics , Parapoxvirus/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/therapeutic use , Viral Proteins/genetics , Viral Proteins/immunology , Viral Vaccines/biosynthesis
3.
PLoS One ; 8(12): e83802, 2013.
Article in English | MEDLINE | ID: mdl-24376753

ABSTRACT

Previously we demonstrated the versatile utility of the Parapoxvirus Orf virus (ORFV) as a vector platform for the development of potent recombinant vaccines. In this study we present the generation of new ORFV recombinants expressing the hemagglutinin (HA) or nucleoprotein (NP) of the highly pathogenic avian influenza virus (HPAIV) H5N1. Correct foreign gene expression was examined in vitro by immunofluorescence, Western blotting and flow cytometry. The protective potential of both recombinants was evaluated in the mouse challenge model. Despite adequate expression of NP, the recombinant D1701-V-NPh5 completely failed to protect mice from lethal challenge. However, the H5 HA-expressing recombinant D1701-V-HAh5n mediated solid protection in a dose-dependent manner. Two intramuscular (i.m.) injections of the HA-expressing recombinant protected all animals from lethal HPAIV infection without loss of body weight. Notably, the immunized mice resisted cross-clade H5N1 and heterologous H1N1 (strain PR8) influenza virus challenge. In vivo antibody-mediated depletion of CD4-positive and/or CD8-posititve T-cell subpopulations during immunization and/or challenge infection implicated the relevance of CD4-positive T-cells for induction of protective immunity by D1701-V-HAh5n, whereas the absence of CD8-positive T-cells did not significantly influence protection. In summary, this study validates the potential of the ORFV vectored vaccines also to combat HPAIV.


Subject(s)
Hemagglutinin Glycoproteins, Influenza Virus/genetics , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Orf virus/genetics , Viral Vaccines/genetics , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , Chlorocebus aethiops , DNA, Recombinant/genetics , Gene Expression , Immunization , Mice , Nucleoproteins/genetics , Nucleoproteins/immunology , T-Lymphocyte Subsets/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vero Cells
4.
J Virol ; 87(3): 1618-30, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23175365

ABSTRACT

The present study describes the generation of a new Orf virus (ORFV) recombinant, D1701-V-RabG, expressing the rabies virus (RABV) glycoprotein that is correctly presented on the surface of infected cells without the need of replication or production of infectious recombinant virus. One single immunization with recombinant ORFV can stimulate high RABV-specific virus-neutralizing antibody (VNA) titers in mice, cats, and dogs, representing all nonpermissive hosts for the ORFV vector. The protective immune response against severe lethal challenge infection was analyzed in detail in mice using different dosages, numbers, and routes for immunization with the ORFV recombinant. Long-term levels of VNA could be elicited that remained greater than 0.5 IU per ml serum, indicative for the protective status. Single applications of higher doses (10(7) PFU) can be sufficient to confer complete protection against intracranial (i.c.) challenge, whereas booster immunization was needed for protection by the application of lower dosages. Anamnestic immune responses were achieved by each of the seven tested routes of inoculation, including oral application. Finally, in vivo antibody-mediated depletion of CD4-positive and/or CD8-posititve T cell subpopulations during immunization and/or challenge infection attested the importance of CD4 T cells for the induction of protective immunity by D1701-V-RabG. This report demonstrates another example of the potential of the ORFV vector and also indicates the capability of the new recombinant for vaccination of animals.


Subject(s)
Antigens, Viral/immunology , Drug Carriers , Genetic Vectors , Glycoproteins/immunology , Orf virus/genetics , Rabies Vaccines/immunology , Rabies virus/immunology , Viral Envelope Proteins/immunology , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Antigens, Viral/genetics , CD4-Positive T-Lymphocytes/immunology , Cats , Disease Models, Animal , Dogs , Female , Glycoproteins/genetics , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Rabies/prevention & control , Rabies Vaccines/administration & dosage , Rabies Vaccines/genetics , Rabies virus/genetics , Survival Analysis , Viral Envelope Proteins/genetics
5.
BMC Vet Res ; 8: 114, 2012 Jul 18.
Article in English | MEDLINE | ID: mdl-22809544

ABSTRACT

BACKGROUND: The Orf virus (ORFV), a zoonotic Parapoxvirus, causes pustular skin lesions in small ruminants (goat and sheep). Intriguingly, ORFV can repeatedly infect its host, despite the induction of a specific immunity. These immune modulating and immune evading properties are still unexplained. RESULTS: Here, we describe that ORFV infection of permissive cells impairs the intracellular transport of MHC class I molecules (MHC I) as a result of structural disruption and fragmentation of the Golgi apparatus. Depending on the duration of infection, we observed a pronounced co-localization of MHC I and COP-I vesicular structures as well as a reduction of MHC I surface expression of up to 50%. These subversion processes are associated with early ORFV gene expression and are accompanied by disturbed carbohydrate trimming of post-ER MHC I. The MHC I population remaining on the cell surface shows an extended half-life, an effect that might be partially controlled also by late ORFV genes. CONCLUSIONS: The presented data demonstrate that ORFV down-regulates MHC I surface expression in infected cells by targeting the late vesicular export machinery and the structure and function of the Golgi apparatus, which might aid to escape cellular immune recognition.


Subject(s)
Ecthyma, Contagious/virology , Gene Expression Regulation/physiology , Genes, MHC Class I/physiology , Golgi Apparatus/physiology , Orf virus/physiology , Animals , Antibodies, Monoclonal , Chlorocebus aethiops , Flow Cytometry , Fluorescent Antibody Technique , Genes, MHC Class I/genetics , Protein Transport , Vero Cells
6.
Vaccine ; 27(27): 3584-91, 2009 Jun 02.
Article in English | MEDLINE | ID: mdl-19464538

ABSTRACT

The present study demonstrates the protective potential of novel baculovirus recombinants, which express the glycoproteins gB, gC, or gD of Pseudorabies virus (PRV; Alphaherpesvirus of swine) and additionally contain the glycoprotein G of Vesicular Stomatitis Virus (VSV-G) in the virion (Bac-G-PRV). To evaluate the protective capacity, mixtures of equal amounts of the PRV gB-, gC-, and gD-expressing baculoviruses were used for immunization. Three intramuscular immunizations with that Bac-G-PRV mixture could protect mice against a lethal PRV challenge infection. To achieve complete protection high titers of Bac-G-PRV and three immunizations were necessary. This immunization with Bac-G-PRV resulted in the induction of high titers of PRV-specific serum antibodies of the IgG2a subclass and of interferon (IFN)-gamma, indicating a Th1-type immune response. Moreover, splenocytes of immunized mice exhibited natural killer cell activity accompanied by the production of IFN-alpha and IFN-gamma. Collectively, the presented data demonstrate for the first time that co-expression of VSV-G in baculovirus recombinant vaccines can improve the induction of a protective immune response against foreign antigens.


Subject(s)
Baculoviridae/genetics , Herpesvirus 1, Suid/immunology , Vaccines, Synthetic/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Interferon-gamma/biosynthesis , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Mice , Mice, Inbred BALB C , Viral Envelope Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...